HEARING IMPAIRMENT AND OTHER COMMUNICATION DISORDERS ASSOCIATED WITHCMV INFECTION, HIV INFECTION, AND AIDS NIH GUIDE, Volume 21, Number 34, September 25, 1992 PA NUMBER: PA-92-107 P.T. 34 Keywords: Communicative Disorders, Hearing AIDS National Institute on Deafness and Other Communication Disorders PURPOSE The Division of Communication Sciences and Disorders of the National Institute on Deafness and Other Communication Disorders (NIDCD) encourages grant applications seeking support for innovative research in the area of hearing impairment and other communication disorders in persons with cytomegalovirus (CMV) infection, human immunodeficiency virus (HIV) infection or with acquired immunodeficiency syndrome (AIDS). Research is needed to clarify the role of CMV, HIV, AIDS, and therapeutic agents used in the treatment of these diseases in the etiology of hearing loss and other communication disorders. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Program Announcement (PA), Hearing Impairment and Other Communication Disorders Associated with CMV Infection, HIV Infection, and AIDS, is related to the priority area of HIV infection. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-11474-0 or Summary Report: Stock No. 017-001-11473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support mechanisms for the announcement include the individual research project grant (R01) and the First Independent Research Support and Transition (FIRST) Award (R29). Foreign institutions are not eligible for the FIRST Award. RESEARCH OBJECTIVES Background Congenital CMV infection is the leading cause of nonhereditary deafness in children. The most frequent sequela associated with congenital CMV infection is hearing loss. It has been estimated that congenital CMV infection accounts for about 40,000 cases of sensorineural hearing loss per year in the United States. Some studies have shown that more than 90 percent of AIDS patients are co-infected with CMV. Current estimates from the Centers for Disease Control indicate that over 1.7 million Americans are infected with HIV. During the course of the disease, the infection progresses in stages from an initial asymptomatic state, to AIDS-related complex, and AIDS characterized by systemic immune deficiency and opportunistic infection. Case reports indicate that auditory and vestibular dysfunction may occur in HIV-infected persons and the symptoms may develop in early stages of infection. Although infection of the central nervous system by HIV is well documented, the pathophysiology of auditory impairment in HIV-infected individuals is not known. Hearing disorders in AIDS patients could be caused by infection of the cochlea and auditory nerve with CMV or HIV. Additionally, hearing loss in these patients could be due to other opportunistic infections or treatment with ototoxic antimicrobial therapeutic agents. Studies are needed to document auditory abnormalities in CMV- and HIV-infected persons so that appropriate early treatment might be provided. In addition to auditory and vestibular disorders, patients with AIDS may experience other communication difficulties. Kaposi sarcomas often occur in the mouth, pharynx, and larynx and can cause respiratory, swallowing, phonatory and articulatory difficulties. Neurogenic components associated with AIDS may include both motor speech and language disorders. An estimated 20,000 to 30,000 children in the United States are HIV positive; thus, speech-language pathologists, audiologists, and otolaryngologists are inevitably involved in the diagnosis and treatment of CMV- and HIV-positive children. Research Goals and Scope Improved treatment for AIDS patients has increased the postdiagnosis quality and expectation of life. Disorders of hearing, balance, smell, taste, speech, voice, and language represent a quality of life issue that increases in importance as the survival period is extended in HIV-infected individuals. The ultimate goal of this announcement is to increase the understanding of the etiology and pathophysiology of communication impairments during CMV infection, HIV infection, and AIDS and to use this information to improve treatment and quality of life. Innovative, state-of-the-art, multidisciplinary clinical and basic studies are encouraged. Studies may include, but are not limited to, the topics listed below as they relate to the communication disorders of hearing, balance, taste, smell, voice, speech, and language: o development of quantitative, objective techniques for early detection, evaluation, and prognosis of developing communication dysfunction in CMV- and HIV-infected persons; o establishment of an epidemiological surveillance system to estimate the incidence and prevalence of communication disorders due to these viral infections in different populations; o development of the means for identifying and classifying communication disorders in CMV- and HIV-infected children and adults; o examination of the potential ototoxic properties of antifungal, antibacterial, and antiviral agents (such as zidovudine, zalcitabine, and didanosine); o determination of the pathophysiology of these viral infections within the peripheral and central auditory nervous system; o identification of the cellular and molecular mechanisms specific to these viral infections of sensory cells; o identification of the specific intra- and extracellular biochemical, metabolic, enzymatic, and protein changes associated with these viral infections of sensory cells; o development of animal or in vitro models to address the viral pathogenesis in sensory cells and tissues in immunocompetent and immunodeficient subjects; o examination and correlation of the interactions between primary infection and opportunistic cofactors in exacerbating damage to sensory cells and tissues (including cytomegalovirus, pneumocystis carinii, and candidiasis); o examination of maternal immunosuppression effects on the pathogenesis of CMV infection in the placenta and fetal auditory system; o assessment of CMV infection, HIV infection, or AIDS on communication disorders throughout the life cycle, including critical developmental periods and aging; and o determination of appropriate communicative and sensory therapeutic and rehabilitative protocols for communication disorders associated with CMV infection, HIV infection, and AIDS. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements are required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis must be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale must be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues must be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information must be included in the form PHS 398 in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, the NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans [including American Indians or Alaskan Natives], Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research is defined as human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether or not the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and reflected in assigning the priority score to the application. All applications for clinical research submitted to the NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91) and will be accepted at the standard application deadlines as indicated in the application kit. The receipt dates for applications for AIDS-related research differ from the standard deadlines and are found in the PHS 398 instructions. Application kits are available at most institutional business offices and may be obtained from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301-496-7441. The title and number of this announcement must be typed in Section 2a on the face page of the application. The completed original application and five exact copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW CONSIDERATIONS Applications will be reviewed for scientific and technical merit by study sections of the Division of Research Grants, NIH, in accordance with the standard NIH peer review procedures. Following scientific-technical review, the applications will receive a second-level review by the appropriate National Advisory Council. AWARD CRITERIA Applications will compete for available funds with all other approved applications. The following will be considered as funding decisions are made: o Quality of the proposed project as determined by peer review o Availability of funds o Program balance among research areas of the announcement INQUIRIES For additional information regarding programmatic issues, investigators are encouraged to call or write to NIDCD staff responsible for grants in the investigator's particular area of scientific interest: Dr. Beth Ansel (voice,speech) (301-402-3461) Dr. Judith Cooper (language) (301-496-5061) Dr. Amy Donahue (hearing) (301-402-3458) Dr. Jack Pearl (taste) (301-402-3464) Dr. Rochelle Small (smell) (301-496-3464) Dr. Daniel Sklare (balance/vestibular) (301-402-3461) Division of Communication Sciences and Disorders National Institute on Deafness and Other Communication Disorders Executive Plaza South, Suite 400-B 6120 Executive Boulevard Rockville, MD 20892 Direct inquiries regarding fiscal matters to: Sharon Hunt Grants Management Officer Division of Extramural Activities National Institute on Deafness and Other Communication Disorders Executive Plaza South, Suite 400-B 6120 Executive Boulevard Rockville, MD 20892 Telephone: (301) 402-0909 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.173. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |